1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study
Sponsor: Boehringer Ingelheim
Listed as NCT00153023, this PHASE4 trial focuses on Diabetic Nephropathies and Hypertension and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 7 times since 2003, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Apr 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Almería, Spain , Amiens, France , Aschaffenburg, Germany , Bad Mergentheim, Germany , Banská Bystrica, Slovakia , Barcelona, Spain , Beauvais, France , Berlin, Germany , Bilbao, Spain , Bologna, Italy and 80 more locations